Wells Fargo & Company Cyclacel Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.28 - $0.75 $0 - $0	1 Added 0.17%	580 $0
Q2 2023 Aug 15, 2023	BUY	$0.52 - $0.76 $2 - $3	4 Added 0.7%	579 $0
Q1 2023 May 12, 2023	BUY	$0.56 - $1.15 $0 - $1	1 Added 0.17%	575 $0
Q4 2022 Feb 13, 2023	BUY	$0.54 - $21.75 $1 - $43	2 Added 0.35%	574 $0
Q3 2022 Nov 14, 2022	BUY	$1.23 - $21.9 $12 - $219	10 Added 1.78%	572 $1,000
Q2 2022 Aug 12, 2022	BUY	$6.1 - $7.15 $30 - $35	5 Added 0.9%	562 $1,000
Q1 2022 May 16, 2022	BUY	$5.93 - $7.6 $23 - $30	4 Added 0.72%	557 $2,000
Q3 2021 Nov 15, 2021	SELL	$8.02 - $11.0 $16 - $22	-2 Reduced 0.36%	553 $3,000
Q2 2021 Aug 16, 2021	SELL	$7.59 - $10.48 $22,671 - $31,303	-2,987 Reduced 84.33%	555 $3,000
Q1 2021 May 13, 2021	BUY	$6.86 - $9.24 $20,682 - $27,858	3,015 Added 572.11%	3,542 $25,000
Q3 2020 Nov 05, 2020	BUY	$4.81 - $6.49 $105 - $142	22 Added 4.36%	527 $2,000
Q2 2020 Aug 13, 2020	BUY	$5.2 - $7.75 $2,626 - $3,913	505 New	505 $2,000

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $4.64M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.